UNIV DEGLI STUDI MAGNA GRAECIA CATANZARO has a total of 11 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in EPO (European Patent Office), Australia and Brazil. Its main competitors in its focus markets pharmaceuticals, measurement and biotechnology are ONCOMED PHARMACEUTICAL INC, DINONA and ARBELE LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 2 | |
#2 | Australia | 1 | |
#3 | Brazil | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Israel | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Mexico | 1 | |
#9 | United States | 1 | |
#10 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Biotechnology | |
#4 | Computer technology |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds | |
#5 | Bioinformatics |
# | Name | Total Patents |
---|---|---|
#1 | Tassone Pierfrancesco | 7 |
#2 | Pierfrancesco Tassone | 2 |
#3 | Gentile Francesco | 1 |
#4 | Coppede Nicola | 1 |
#5 | Malara Natalia | 1 |
Publication | Filing date | Title |
---|---|---|
EP3650864A2 | Method for diagnosing cancer and kit therefor | |
CN110291107A | Target the monoclonal antibody of the glycosylated cancer associated epitope of unique sialic acid of CD43 |